Biotechnology M&A » By The Online Investor Staff, updated Thu., Apr. 25, 5:35 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #80 of 83 |
Slide #80. Illumina — BlueGnome Ltd.
Acquirer:
Illumina (NASDAQ:ILMN)
Acquiree:
BlueGnome Ltd.
Details:
Illumina, Inc. announced that it has acquired Cambridge, U.K.-based BlueGnome Ltd. for an undisclosed sum. BlueGnome, now a wholly owned subsidiary of Illumina, is a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility.
Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co.'s products and services enable the adoption of genomic solutions in research and clinical settings. Co.'s principal products, services, and technologies are: sequencing, which includes Deoxyribonucleic acid (DNA) sequencing, a process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample; arrays, which are used for a range of DNA and RNA analysis applications; consumables, which Co. has developed various library preparation and sequencing kits; and services, which provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
ILMN SEC Filing Email Alerts Service
Open the ILMN Page at The Online Investor »
|
||||||||||||||||||||||||
Open the ILMN Page at The Online Investor (in a new window) »
 Free ILMN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (2.78 out of 4) 16th percentile
(ranked lower than approx. 84% of all stocks covered)
Analysts' Target Price: ILMN Stock Forecast Based on Zacks ABR data; powered by Xignite |
